Publicación:
Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.

Vista sencilla de ítem
dc.contributor.authorPuentes Puentes, Luis Orlandospa
dc.contributor.authorAmaya Pino, Juan Pablospa
dc.date.accessioned2016-07-15 00:00:00
dc.date.available2016-07-15 00:00:00
dc.date.issued2016-07-15
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.32997/rcb-2016-2856
dc.identifier.eissn2389-7252
dc.identifier.issn2215-7840
dc.identifier.urlhttps://doi.org/10.32997/rcb-2016-2856
dc.language.isospaspa
dc.publisherUniversidad de Cartagenaspa
dc.relation.bitstreamhttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2856/2399
dc.relation.citationeditionNúm. 2 , Año 2016spa
dc.relation.citationendpage284
dc.relation.citationissue2spa
dc.relation.citationstartpage274
dc.relation.citationvolume7spa
dc.relation.ispartofjournalRevista Ciencias Biomédicasspa
dc.relation.referencesBie Y, Zhang Z. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis. World J Surg Oncol. 2014; 12:169. https://doi.org/10.1186/1477-7819-12-169spa
dc.relation.referencesNCCN. Clinical practice gidelines in oncology. Uterine Neoplasms version 2.2016 2016.spa
dc.relation.referencesWorld Health Organization, International Agency for Research on Cancer. Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Geneve: The Organization; 2015 [cited 2015/11/05]. Available from: http://globocan.iarc.fr/Default.aspxspa
dc.relation.referencesPardo-Ramos C, Cendales-Duarte R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Instituto Nacional de Cancerología. 2015.spa
dc.relation.referencesBurke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014; 134(2): 385-92. https://doi.org/10.1016/j.ygyno.2014.05.018spa
dc.relation.referencesPike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997; 89(15): 1110-6. https://doi.org/10.1093/jnci/89.15.1110spa
dc.relation.referencesFisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86(7): 527-37. https://doi.org/10.1093/jnci/86.7.527spa
dc.relation.referencesSoliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006; 106(11): 2376-81. https://doi.org/10.1002/cncr.21866spa
dc.relation.referencesSoler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension. 1999; 34(2): 320-5. https://doi.org/10.1161/01.HYP.34.2.320spa
dc.relation.referencesMcPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol. 1996; 143(12): 1195-202. https://doi.org/10.1093/oxfordjournals.aje.a008707spa
dc.relation.referencesTimmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010; 116(1): 160-7. https://doi.org/10.1097/AOG.0b013e3181e3e7e8spa
dc.relation.referencesEpstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 2001; 80(12): 1131-6. https://doi.org/10.1034/j.1600-0412.2001.801210.xspa
dc.relation.referencesDijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000; 89(8): 1765-72. https://doi.org/10.1002/1097-0142(20001015)89:81765::AID-CNCR173.0.CO;2-Fspa
dc.relation.referencesConnor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000; 95(5): 692-96. https://doi.org/10.1097/00006250-200005000-00012spa
dc.relation.referencesKitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol. 2009; 19(6): 1529-36. https://doi.org/10.1007/s00330-008-1271-8spa
dc.relation.referencesOmer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S, et al. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol. 2013; 34(5): 2645-50. https://doi.org/10.1007/s13277-013-0814-zspa
dc.relation.referencesMoore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008; 110(2): 196-201. https://doi.org/10.1016/j.ygyno.2008.04.002spa
dc.relation.referencesZanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012; 50(12): 2189-98. https://doi.org/10.1515/cclm-2011-0757spa
dc.relation.referencesJiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, et al. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci. 2013; 14(11): 22655-77. https://doi.org/10.3390/ijms141122655spa
dc.relation.referencesGalgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19(6): 847-53. https://doi.org/10.1038/modpathol.3800612spa
dc.relation.referencesZhang AM, Zhang P. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA (125) in the diagnosis of endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2012; 47(2): 125-8.spa
dc.relation.referencesAngioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013; 34(1): 571-6. https://doi.org/10.1007/s13277-012-0583-0spa
dc.relation.referencesBignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011; 104(9): 1418-25. https://doi.org/10.1038/bjc.2011.109spa
dc.relation.referencesKemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, et al. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol. 2016; 140(1): 64-9. https://doi.org/10.1016/j.ygyno.2015.11.020spa
dc.relation.referencesKalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012; 124(2): 270-5. https://doi.org/10.1016/j.ygyno.2011.10.025spa
dc.relation.referencesDobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kinalski M, Terlikowski SJ. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy. Adv Med Sci. 2016; 61(1): 23-7. https://doi.org/10.1016/j.advms.2015.07.010spa
dc.relation.referencesMutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012; 126(2): 186-91. https://doi.org/10.1016/j.ygyno.2012.04.022spa
dc.relation.referencesSaarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Am J Obstet Gynecol. 2013; 209(2): 142.e1-6. https://doi.org/10.1016/j.ajog.2013.04.014spa
dc.relation.referencesAntonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand. 2013; 92(11): 1313-22. https://doi.org/10.1111/aogs.12235spa
dc.relation.referencesCapriglione S, Plotti F, Miranda A, Ricciardi R, Scaletta G, Aloisi A, et al. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. Tumour Biol. 2015; 36(6): 4151-6. https://doi.org/10.1007/s13277-015-3049-3spa
dc.relation.referencesBrennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, et al. Serum HE4 as a prognostic marker in endometrial cancer a population based study. Gynecol Oncol. 2014; 132(1): 159-65. https://doi.org/10.1016/j.ygyno.2013.10.036spa
dc.relation.referencesMoore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2011; 21(7): 1185-90. https://doi.org/10.1097/IGC.0b013e3182229ad8spa
dc.relation.referencesMinar L, Klabenesova I, Jandakova E, Zlamal F, Bienertova-Vasku J. Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging. J Obstet Gynaecol Res. 2015; 41(10): 1644-52. https://doi.org/10.1111/jog.12764spa
dc.relation.referencesBenedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008; 100(23): 1707-16. https://doi.org/10.1093/jnci/djn397spa
dc.relation.referencesKitchener H, Swart AM, Qian Q, Amos C, Parmar MK, group As. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373(9658): 125-36. https://doi.org/10.1016/S0140-6736(08)61766-3spa
dc.relation.referencesTodo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010; 375(9721): 1165-72. https://doi.org/10.1016/S0140-6736(09)62002-Xspa
dc.relation.referencesAngioli R, Capriglione S, Scaletta G, Aloisi A, Miranda A, De Cicco Nardone C, et al. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. Tumour Biol. 2016; 37(4): 4973-78. https://doi.org/10.1007/s13277-015-4324-zspa
dc.relation.referencesBrennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer. 2015; 15:33. https://doi.org/10.1186/s12885-015-1028-0spa
dc.rightsRevista Ciencias Biomédicas - 2016spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.creativecommonsEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourcehttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2856spa
dc.subjectNeoplasia endometrialspa
dc.subjectEndometriospa
dc.subjectBiopsiaspa
dc.subjectEndometrial neoplasmeng
dc.subjectEndometriumeng
dc.subjectBiopsyeng
dc.titleRendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.spa
dc.title.translatedHE4 performance in the diagnosis, prognosis and prediction of relapse in endometrial cancer.eng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.localJournal articleeng
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication

Archivos

Colecciones

Revista Ciencias Biomédicas - Portal de Revistas

Datos de Contacto

Imagen Escudo Universidad de Cartagena

 

 

 

Sede: Claustro de San Agustín, Centro Histórico, Calle de la Universidad Cra. 6 #36-100
Colombia, Bolívar, Cartagena
Ver más...

Línea de Atención

Línea Anticorrupción

Síguenos en: